Search | Clinical Trials Finder

Conditions: Healthy Participants
Interventions: AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Drug Pharmacokinetics in Healthy Volunteers
Interventions: DS-8500a, Rosuvastatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2248761, Simvastatin, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections
Interventions: darunavir, ritonavir, rosuvastatin, rosuvastatin, darunavir, ritonavir; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Atorvastatin, Pravastatin, Rosuvastatin, Filgotinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Familial Hypercholesterolaemia
Interventions: rosuvastatin calcium; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Renal Insufficiency
Interventions: Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Crohn's Ileocolitis, Crohn Disease
Interventions: Rosuvastatin, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions: ABT-143, simvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 129
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more

Conditions: Familial Hypercholesterolemia
Interventions: Rosuvastatin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Los Angeles, California • Hyde Park, New York • Cincinnati, Ohio + 1 more

Conditions: Friedreich Ataxia
Interventions: Rosuvastatin; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: Atorvastatin, ALG-055009, Rosuvastatin; Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Atherosclerosis
Interventions: Rosuvastatin 10 mg, Darapladib 160 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: TP53 Y220C Mutation, Advanced Solid Tumors
Interventions: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more

Conditions: Healthy
Interventions: Efavirenz, Bupropion, Rosuvastatin, Montelukast; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Advanced Solid Tumors, Metastatic Melanoma
Interventions: losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: HIV Infections, Cardiovascular Disease
Interventions: rosuvastatin; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Healthy, Obese, Overweight
Interventions: Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, Midazolam, Sodium Bicarbonate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
Interventions: Polypill, Usual Care (individual medications prescribed by primary cardiologist); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: TERN-701, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine; Drug
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Millcreek, Utah

Conditions: Healthy
Interventions: Warfarin, warfarin plus ABT-335 plus rosuvastatin 5 mg, warfarin plus ABT-335 plus rosuvastatin 20 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions: ABT-335, Rosuvastatin Calcium, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 1,445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Healty Volunteers
Interventions: KP-001, Rosuvastatin calcium10mg, Caffeine citrate, Fluvoxamine; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

Effect of Statins on Crohn's Disease

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin

Rosuvastatin (Crestor) in Friedreich Ataxia

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Effect of Rosuvastatin on Endothelial Function

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

Polypill in Acute Coronary Syndrome

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)

Interaction Between ABT-335, Rosuvastatin and Warfarin

Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers